AstraZeneca to build $200m center in China

    Updated: 2011-10-12 09:56

    By Ma Zhenhuan (China Daily)

      Comments() Print Mail Large Medium  Small 分享按鈕 0

    AstraZeneca to build $200m center in China

    AstraZeneca PLC workers load blister strips onto a packing line at a factory in Macclesfield, United Kingdom. The UK-based medical company will create 600 jobs by building a new factory in Taizhou, Jiangsu province. [Photo / Bloomberg]

    SHANGHAI - AstraZeneca PLC, one of the world's leading pharmaceutical companies, said it would invest $200 million to launch a new manufacturing facility in China to meet growing demand, including in rural areas.

    Construction work on the project, in the China Medical City in Taizhou of East China's Jiangsu province, is scheduled for completion by the end of 2013, creating approximately 600 jobs.

    This will be London-based AstraZeneca's largest single investment in a manufacturing facility globally. The new plant will produce intravenous and oral solid products, the company said.

    "The new facility will significantly enhance our capacity and allow us to meet the growing healthcare demand of the Chinese population, and help us expand into the 900 million (rural) people outside of the big cities and hospitals," Mark Mallon, president of AstraZeneca China, told China Daily in an exclusive interview on Monday.

    "It will also allow us to free up some capacity at our existing manufacturing facility in Wuxi, Jiangsu, to bring on more new innovative products that will be launched over the next few years," he added.

    The Chinese pharmaceutical market grew from $10 billion in 2004 to $41 billion in 2010, according to market research agency IMS Health Inc, and it is expected to reach $102 billion by 2015.

    Mallon said that he believes the Chinese government's focus on healthcare reform and investment in improving healthcare infrastructure and expanding insurance coverage will continue to drive the company's business growth and increase access to quality medicines over the longer term.

    AstraZeneca will launch two new products, Faslodex, a treatment for breast cancer, and Onglyza, a new treatment for Type-2 Diabetes, in China this year.

    Mallon also mentioned that the company is planning to launch Brilinta, an oral antiplatelet treatment for acute coronary syndrome, next year in China.

    With an enhanced manufacturing capacity and the launch of more innovative new medicines, the company is planning to produce more affordable medicines for Chinese patients. It will adopt a multi-channel approach to sell its products to markets beyond big cities and hospitals.

    Aside from the medical sales representatives who deal with individual physicians in big cities, the company has developed a team of about 100 customer service representatives who organize educational programs for small clinics and community health centers in China's rural areas.

    It will also set up an inbound and outbound call center to reach out to healthcare professionals through phone calls, helping them learn more about AstraZeneca products, he said.

    The company, which entered China in 1993, has invested about $500 million in the country, including an innovation center in Zhangjiang, Shanghai.

    最近更新中文字幕第一页| 97无码免费人妻超级碰碰夜夜| 国产网红无码精品视频| 中文字幕视频在线| 无码少妇一区二区浪潮av| 亚洲熟妇无码乱子AV电影| 波多野结衣中文在线播放| 国产精品无码一区二区在线观一| 中文字幕亚洲无线码| 中文字幕无码第1页| A∨变态另类天堂无码专区| 欧美日韩毛片熟妇有码无码| 中文字幕乱码久久午夜| 国产亚洲美日韩AV中文字幕无码成人 | 无码永久免费AV网站| 日本久久中文字幕| 中文无码制服丝袜人妻av| 蜜臀AV无码国产精品色午夜麻豆| 无码人妻久久一区二区三区免费丨 | 中文无码精品一区二区三区| 丰满人妻AV无码一区二区三区| 野花在线无码视频在线播放| 欧美日韩中文字幕在线观看| 中文国产成人精品久久不卡| 亚洲成?v人片天堂网无码| 精品久久久久久无码人妻热| 国产精品三级在线观看无码| 无码人妻精品一区二区三区东京热| 在线看片福利无码网址| 无码毛片一区二区三区中文字幕| 日韩精品无码中文字幕一区二区| 最近免费中文字幕MV在线视频3| 免费VA在线观看无码| 精品久久久久久无码中文野结衣| 成 人无码在线视频高清不卡| 国产成人精品无码播放| 成?∨人片在线观看无码| 99久久无码一区人妻a黑 | 亚洲?V无码乱码国产精品| 久久精品无码专区免费 | 中文国产成人精品久久亚洲精品AⅤ无码精品|